Cancer Research Meeting Calendar Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, Y.
Right arrow Articles by Qiao, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, Y.
Right arrow Articles by Qiao, L.
[Cancer Research 65, 6990-6999, August 1, 2005]
© 2005 American Association for Cancer Research

Immunology

Induction of Mucosal and Systemic Immune Responses against Human Carcinoembryonic Antigen by an Oral Vaccine

Yujun Huang, Raja Fayad, Andrew Smock, Amanda M. Ullrich and Liang Qiao

Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois

Requests for reprints: Liang Qiao, Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153. Phone: 708-327-3481; Fax: 708-216-1196; E-mail: lqiao{at}lumc.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Carcinoembryonic antigen (CEA) is a tumor-associated antigen targeted for the development of colorectal tumor vaccines. In this study, we developed papillomavirus pseudoviruses encoding the truncated CEA without NH2-terminal signal peptide (PV-CEA) as an oral vaccine to induce CEA-specific CTL responses. In CEA transgenic (CEA-Tg) mice orally immunized with PV-CEA, the immunologic tolerance to CEA as a "self-antigen" was overcome and both mucosal and systemic CEA-specific cytolytic activities were detected by in vitro 51Cr release assays. In a tumor prevention model, the growth rate of CEA+ tumors was significantly delayed in CEA-Tg mice orally immunized with PV-CEA when compared with the control vaccine. Further, the IFN-{gamma} enzyme-linked ImmunoSPOT and in vitro 51Cr release assay results showed that HLA-A2-restricted, CEA-specific CTL responses were induced in both mucosal and systemic lymphoid tissues in A2 transgenic mice after oral immunization with PV-CEA. Finally, we showed that coadministration of papillomavirus pseudoviruses encoding interleukin-2 with PV-CEA enhanced the generation of A2-restricted, CEA-specific CTLs in aged CEA/A2 double transgenic mice, which were more clinically relevant. Our data suggest that PV-CEA pseudovirus vaccine is a promising oral CEA vaccine for humans to induce CEA-specific CTLs at the site of colorectal tumors (i.e., intestinal mucosa), which might efficiently eliminate CEA+ colorectal tumor cells in the mucosa.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Carcinoembryonic antigen (CEA) is a 180-kDa cell surface glycoprotein extensively expressed in the majority of colon, rectal, stomach, and pancreatic cancers, 70% of non–small cell lung cancers and 50% of breast cancers (1–3). It is usually expressed at lower concentrations in normal adult colonic epithelia. Due to its unique expression pattern, it has been targeted as a tumor-associated antigen to induce CEA-specific antibodies, CD4+ T helper cells, and CD8+ CTLs to treat CEA+ tumors (4). However, like many other tumor-associated antigens, CEA is a "self-antigen" usually expressed during fetal development and later in normal colonic epithelia at low levels. To evaluate vaccines directed against CEA as a self-antigen, a useful animal model was provided by the establishment of mice that carry the transgene for human CEA and express CEA in a tissue-specific manner similar to humans (5–9).

In CEA transgenic (CEA-Tg) mice, peripheral T-cell tolerance to CEA was shown by the absence of any immune response to either endogenous CEA or after vaccination with the CEA protein in adjuvant (9). However, the immunologic tolerance to CEA is not absolute. When CEA-Tg mice were immunized with recombinant poxvirus-based vaccines (9–13), CEA-transfected syngeneic fibroblasts in combination with Corynebacterium parvum (14), dendritic cells pulsed with anti-idiotype antibody mimicking CEA (15, 16), DNA vaccines encoding CEA absorbed onto cationic microparticles (17), or an oral vaccine using attenuated bacteria encoding CEA (18–20), tolerance to this self-tumor–associated antigen was overcome as evidenced by the development of CEA-specific antibody, CD4+ T helper cells, and CD8+ CTL responses.

In humans, CEA-specific immune responses were also elicited under certain circumstances. It has been shown that CEA contains multiple HLA-restricted CTL epitopes (21–26). CD8+ MHC-restricted CTLs capable of lysing autologous tumors expressing CEA have been isolated from patients vaccinated with recombinant poxviruses expressing CEA (27–29). CEA-specific CTLs can also be generated in vitro by antigen-presenting cells (APC) pulsed with synthetic CEA peptides or CEA RNA (24–26, 30).

Papillomaviruses are a group of small DNA viruses that infect mucosa and skin. Their major structural protein L1 can be assembled spontaneously into virus-like particles (VLP) when expressed in insect cells, yeasts, and bacteria (31–36). Papillomavirus VLPs can be used to package unrelated plasmids to form papillomavirus pseudoviruses (37–39). We have shown that VLPs can be used as a mucosal vaccine carrier to deliver plasmids encoding the genes of interest into mucosal and systemic lymphoid tissues, and oral immunization with papillomavirus pseudoviruses induces mucosal and systemic CTL responses specific for the target antigens (39–41). Therefore, in this study, we developed papillomavirus pseudoviruses encoding the truncated CEA without NH2-terminal signal peptide (PV-CEA) as an oral vaccine to induce intestinal mucosal and systemic CEA-specific CTL responses, which are critical for treating CEA+ colorectal tumors. We determined the immunogenicity of PV-CEA pseudoviruses in CEA-Tg mice and HLA-A2 transgenic (A2-Tg) mice. Furthermore, we explored the approach to induce CEA-specific CTLs in aged CEA/A2 double transgenic mice, which provides a more clinically relevant animal model.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice. C57BL/6 mice and A2-Tg breeder mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice carrying the gene for human CEA (CEA-Tg mice) were originally obtained from Dr. John Thompson (University of Freiburg, Freiburg, Germany) and kindly provided by Drs. John W. Greiner and Jeffrey Schlom (National Cancer Institute, NIH, Bethesda, MD). The CEA-Tg mouse colony was maintained with continuous backcrossing with C57BL/6 mice. A2-Tg mice were generated by in-house breeding. CEA/A2 double transgenic mice were generated by crossing male CEA-Tg mice with female A2-Tg mice. Mice were maintained under specific pathogen-free conditions in the Loyola University Comparative Medicine Facility (Maywood, IL). All experimental procedures were carried out according to the protocols approved by the Institutional Animal Care and Use Committee.

Screening of carcinoembryonic antigen, A2, and carcinoembryonic antigen/A2 double transgenic mice. PCR was used to identify CEA+ and A2+ transgenic mice. Mouse genomic DNA was extracted from mouse tails. DNA (100-200 ng) was used for PCR in a 50 µL reaction volume. The CEA PCR was done as described previously (9). At the end of experiments, the CEA expression in CEA-Tg mice was confirmed by CEA ELISA (Calbiotech, Inc., Spring Valley, CA) using the mouse sera. For the A2 PCR, the sequences for A2-specific primers were GAGGTATTTCTTCACATCCGTG and CGCTCTGGTTGTAGTAGCCGCG. The amplification program consisted of 94°C for 3 minutes, 35 cycles of 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds, and a final 72°C for 7 minutes. The A2 expression on the cell surface was confirmed by flow cytometry after immunostaining using BB7.2 hybridoma culture supernatant (American Type Culture Collection, Manassas, VA).

Cell lines. The human colorectal adenocarcinoma cell line SW1116 was obtained from American Type Culture Collection and cultured in complete Leibovitz's L-15 medium containing 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA). RMA (H-2b) is a murine lymphoma cell line and was maintained in complete RPMI 1640 containing 10% FBS, 2 mmol/L glutamine, 5 x 10–5 mol/L ß-mercaptoethanol, and 100 units/mL penicillin-100 µg/mL streptomycin (all from Invitrogen). RMA-CEA cells are RMA cells transfected with the plasmid DNA pCI-CEA, which encodes the truncated CEA without NH2-terminal signal peptide. RMA-CEAFL cells are RMA cells transfected with the plasmid DNA pCI-CEAFL, which encodes the full-length CEA polypeptide. RMA-neo cells are RMA cells transfected with the empty vector pCI-neo. EL4-A2Kb is a transfectant of the EL4 thymoma that expresses the {alpha}1 and {alpha}2 domains of human HLA-A2 in association with the {alpha}3 domain of murine H2-Kb, which was kindly provided by Dr. W.M. Kast (Loyola University Chicago; ref. 42). All these transfectants were maintained in complete RPMI 1640 containing 500 µg/mL G418 (Invitrogen). All cells were cultured in a humidified incubator at 37°C with 5% v/v CO2.

Construction of expression plasmid pCI-CEA encoding human carcinoembryonic antigen without the NH2-terminal signal peptide and plasmid pCI-CEAFL encoding the full-length carcinoembryonic antigen polypeptide with NH2-terminal signal peptide. RNA was isolated from the human colorectal cancer cell line SW116 using a RNeasy Mini protocol according to the manufacturer's manual (Qiagen, Valencia, CA). DNA contamination was removed by DNase (Qiagen) digestion during RNA purification. Human CEA cDNA was synthesized by reverse transcription using avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI) and the DNA with or without the NH2-terminal signal peptide sequence was amplified by PCR using KlenTaq LA Polymerase Mix (Clontech, Palo Alto, CA). The primers for the CEA without the NH2-terminal signal peptide were CCAGAATTCACCACCATGAAGCTCACTAGGGAATCCACG and AATGCGGCCGCCTATATCAGAGCAACCCCAA; the primers for the full-length CEA were ACCACCATGGAGTCTCCCTCGGCC and AATGCGGCCGCCTATATCAGAGCAACCCCAA. The CEA or CEAFL PCR product was cloned into the TA vector pCR II-TOPO (Invitrogen). Then, the CEA or CEAFL fragment was cut out from the pCR II-CEA or pCR II-CEAFL vector and cloned into mammalian expression vector pCI-neo (Promega) using EcoRI and NotI sites to generate CEA expression plasmid pCI-CEA or pCI-CEAFL. To determine the CEA expression of pCI-CEA in mammalian cells, we transfected 5 x 106 murine RMA cells with 5 µg pCI-neo or pCI-CEA using the SuperFect transfection reagent (Qiagen). The transfectants were selected with 1 mg/mL G418. To determine the CEA protein expression in RMA-CEA or RMA-CEAFL cells, Western blotting was done using monoclonal mouse anti-CEA antibody (Sigma, St. Louis, MO). In addition, The expression of CEA protein without NH2-terminal signal peptide of pCI-CEA was determined by the in vitro transcription and translation using TNT-Coupled Reticulocyte Lysate System (Promega). To determine the CEA gene transcription in the transfectant RMA-CEA, reverse transcription-PCR (RT-PCR) was done using CEA-specific primers (CCAGAATTCACCACCATGAAGCTCACTATTGAATCCACG and CGGGTATACCCGGAACTGGCCAGTTGC) and Omniscript reverse transcriptase (Qiagen). ß-actin RT-PCR was done as the control using the primers TCGACAACGGCTCCGGCAT and TCGGTGAGCAGCACAGGGT.

Generation of papillomavirus pseudoviruses PV-CEA, PV-CEAFL, and PV-IL-2. Bovine papillomavirus-1 (BPV-1) VLPs were generated using the recombinant baculovirus expression system and purified as described before (39). After dialysis against 10 mmol/L HEPES solution, VLPs (40 µg) were incubated at the condition of 25 mmol/L Tris-HCl (pH 8.0), 15 mmol/L NaCl, 10 mmol/L EGTA, and 20 mmol/L DTT in a final volume of 200 µL at room temperature for 60 minutes. Under this condition, the VLPs were completely disrupted. Then, 1 µg/µL plasmid pCI-CEA or pCI-CEAFL (20 µL) was added and the mixture was diluted by 220 µL reassembly buffer containing 25 mmol/L CaCl2 and 20% DMSO to form VLPs at room temperature for 1 hour. To determine the efficiency of plasmid DNA encapsidation in the VLPs, PV-CEA or PV-CEAFL pseudovirus preparation (100 µL) was treated with 80 units Benzonase (Sigma) for 1 hour at 20°C to digest the DNA outside of VLPs. The sample was then heated at 100°C for 10 minutes to inactivate Benzonase and digested with proteinase K (1 mg/mL) at 55°C for 3 hours. The remaining plasmid DNA was extracted by phenol/chloroform. The amount of plasmid DNA was determined by spectrophotometry and ethidium bromide fluorescent quantitation. As a control, PV-CEA or PV-CEAFL pseudovirus preparation (100 µL) without Benzonase digestion was treated in the same way to extract the DNA to estimate the loss of DNA during the extraction. According to the DNA amounts before and after the extraction in the control without Benzonase treatment and the DNA amount after the extraction for the sample treated with Benzonase, we calculated the amount of the DNA packaged inside of VLPs. The amount of the plasmid DNA packaged inside of VLPs was used to determine the copy numbers of the plasmid DNA. Because one VLP can package only one plasmid (40), we concluded that the copy number of plasmid DNA was equal to the number of PV-CEA or PV-CEAFL pseudovirions. Papillomavirus interleukin (IL)-2 pseudovirues (PV-IL-2) were generated in the same way using the plasmid DNA pcDNA/purIL-2 encoding human IL-2 (41).

Immunizations and tumor challenge. Six- to 8-week-old mice were used for the experiments. For oral immunization, mice were immunized twice at a 2-week interval by oral gavage with either 20 µg BPV VLPs or ~0.8 x 1011 PV-CEA pseudovirions generated from 20 µg BPV VLPs. For tumor challenge experiments, 1 week after the second immunization, 1 x 106 RMA-CEAFL cells were s.c. injected in the right flank. Tumor size was measured every 2 days as a tumor area (mm2) with the largest perpendicular diameters. For s.c. vaccinations, the same dose and immunization interval were used as oral immunizations but by s.c. injection into the lower right flank. For coadministration of PV-IL-2 with PV-CEA orally, 12-month-old mice were given both ~0.8 x 1011 PV-CEA generated from 20 µg BPV VLPs and 0.8 x 1011 PV-IL-2 generated from 20 µg BPV VLPs; as the controls, we used 40 µg BPV VLPs or 0.8 x 1011 PV-CEA generated from 20 µg BPV VLPs plus 20 µg BPV VLPs. Ten days after the second immunization, mice were sacrificed for the subsequent experiments.

Peptide synthesis. CEA526-533 (EAQNTTYL, peptide 1), CEA355-363 (LWWVNNQSL, peptide 2), CEA100-108 (IIYPNASLL, peptide 3), CEA347-355 (PEIQNTTYL, peptide 4), CEA571-579 (CGIQNSVSA, peptide 5), CAP-1 (YLSGANLNL), LCMV Gp33 peptide (KAVYNFATC), and HIV-1 gp160120-128 peptide (KLTPLCVTL) were synthesized (>95% pure) in BioSynthesis (Lewisville, TX) or Sigma-Genosys (The Woodlands, TX). All peptides were dissolved in DMSO to a stock concentration of 5 mg/mL and stored at–70°C.

Isolation of lymphocytes from spleen and Peyer's patches. To isolate splenocytes, mouse spleen was removed and homogenized. RBCs were lysed by ACK lysis buffer. The single-cell suspension was collected by passing splenocytes through 70 µm cell strainers (BD Discovery Labware, Bedford, MA). Then, the cell suspension was incubated in nylon-wool columns (Polysciences, Warrington, PA) for 1 hour at 37°C. The enriched T cells were collected by washing cells through the columns with complete RPMI 1640. To isolate lymphocytes from Peyer's patches, small intestines were flushed with ice-cold PBS to remove fecal contents and visible Peyer's patches were harvested. After homogenization, Peyer's patch cells were passed through 70 µm cell strainers and lymphocytes were isolated by Ficoll gradient separation (Amersham, Piscataway, NJ). There were ~30% of CD8+ T cells and 50% of CD4+ T cells in T-cell-enriched splenocytes used for the subsequent experiments; there were ~5% of CD8+ T cells and 15% of CD4+ T cells in Peyer's patch lymphocytes. There was no significant difference in cell composition for splenocytes and Peyer's patch lymphocytes form different treatment groups (flow cytometry data not shown).

In vitro cytotoxicity assay. The cytotoxicity was measured by a standard 6-hour 51Cr release assay. To determine the mucosal CTL response, Peyer's patch lymphocytes were pooled from four mice per group and were directly used as effector cells for the assay. To determine the systemic CTL response, splenocytes enriched for T cells from each individual mouse were in vitro stimulated for 5 days and then used as effector cells for the assay. Splenocytes enriched for T cells were seeded into 96-well U-bottomed plates (BD Discovery Labware) at 5 x 105 cells per well in 200 µL complete RPMI 1640 with 5 µg/mL CEA peptides and 5% T-stim without concanavalin A (BD Discovery Labware). Irradiated (3,000 rad) splenocytes (1 x 105 cells per well) from naive mice were used as feeder cells for in vitro stimulation. RMA cells (1 x 106) were used as target cells by incubating at 37°C with 200 µCi sodium chromate (Perkin-Elmer, Boston, MA) for 1 hour. After washing thrice, target cells were resuspended in complete RPMI 1640 with 5 µg/mL CEA peptides and incubated for 30 minutes. Target cells were seeded into 96-well V-bottomed plates (Nunc, Rochester, NY) at 2 x 103 cells per well in 100 µL complete RPMI 1640. Effector cells from Peyer's patches or spleen were seeded into triplicate wells containing the target cells at various effector/target (E:T) cell ratios, making a final volume of 200 µL. Plates were incubated at 37°C in a humidified incubator with 5% (v/v) CO2 for 6 hours. Plates were centrifuged, and the supernatant (100 µL) was removed from each well to assess the 51Cr release using a gamma radiation counter (Perkin-Elmer). The percentage of specific lysis (%) was calculated as described previously (40).

IFN-{gamma} enzyme-linked ImmunoSPOT assay. An enzyme-linked ImmunoSPOT (ELISPOT) assay was used to detect CEA-specific, INF-{gamma}-secreting cells after stimulation with the synthetic CEA peptides. Multiscreen 96-well plates (Millipore, Bedford, MA) were coated with 100 µL/well of 5 µg/mL anti-IFN-{gamma} capture antibody (PharMingen, San Diego, CA) in PBS at 4°C overnight. Plates were washed once with 200 µL/well complete RPMI 1640 and blocked with 200 µL/well complete RPMI 1640 at room temperature for 2 hours. Splenocytes enriched for T cells and Peyer's patch lymphocytes were added starting at 1 x 106 or 1 x 105 cells, respectively, per well in triplicate wells with 1:3 serial dilutions. Irradiated splenocytes (1 x 106 cells per well) from naive mice were used as the feeder cells. Cells were cultured in complete RPMI 1640 containing 50 units IL-2 (R&D Systems, Minneapolis, MN) and 5 µg/mL CEA peptides. LCMV-specific, Db-restricted peptide Gp33-41 was used as the control for Db background murine cells and HIV-1-specific A2-restricted peptide was used as the control for A2 background murine cells. After a 40-hour incubation at 37°C and 5% CO2, IFN-{gamma} spots were developed as described previously (40).

Antibody responses. Sera or intestinal washings were collected from CEA-Tg mice orally immunized with PV-CEA, PV-CEAFL, or BPV VLP or control as described previously (41). The samples were used for detection of anti-CEA antibody response by ELISA. The plates were coated for overnight with 100 µL/well CEA (Fitzgerald, Concord, MA) at a concentration of 1 µg/mL. Wells were blocked with PBS containing 5% bovine serum albumin for 1 hour. The plates were incubated with diluted mouse serum (1:10-1:10,000) or intestinal washings (1-1:1,000) for 1 hour followed by 1-hour incubation with horseradish peroxidase (HRP)–conjugated rabbit anti-mouse IgM + IgG (Pierce, Rockford, IL) or HRP-conjugated goat anti-mouse IgA ({alpha} chain specific; Sigma). Tetramethyl benzidine (Sigma) was used as the chromogen to develop the color, the reaction was stopped by 2 N H2SO4, and the absorbance was read at 450 nm.

Statistical analysis. Data are reported as means ± SD and analyzed using the SPSS version 8.0 software (SPSS, Chicago, IL) and SAS version 9.1 software (SAS, Cary, NC). P < 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Construction of plasmid pCI-CEA encoding human carcinoembryonic antigen without NH2-terminal signal peptide and plasmid pCI-CEAFL encoding the full-length carcinoembryonic antigen polypeptide with NH2-terminal signal peptide. Generation of CTLs depends on presentation of antigenic peptides by MHC class I molecules. The higher antigen degradation in proteasomes correlates with an enhanced antigen-specific CTL response (43–45). The CEA molecule consists of a 34–amino acid signal peptide followed by a 108–amino acid NH2-terminal IgV-like region; three 178–amino acid IgC-like repeating units called A1B1, A2B2, and A3B3, respectively; and a 26–amino acid COOH-terminal hydrophobic domain replaced by glycosylphosphatidylinositol (GPI; ref. 46). Its signal peptide directs CEA to the endoplasmic reticulum (ER) and the newly synthesized CEA protein undergoes glycosylation, GPI anchor addition, folding, and transport to the cell surface as a membrane-bound protein. We expected that preventing entry into the ER, by deleting the signal peptide, would increase the amount of incorrectly folded molecules resident in the cytosol available as substrates for proteasomal degradation and enhance CEA-specific CTL response. Townsend et al. reported that a deletion of the NH2-terminal signal peptide of influenza hemagglutinin (HA) enhanced the presentation of HA to MHC class I–restricted CTLs (43). Therefore, both a truncated CEA fragment without NH2-terminal signal peptide sequence and a full-length carcinoembryonic antigen fragment with NH2-terminal signal peptide sequence were cloned to compare their immunogenicities.

RNA extracted from a human CEA+ colon cancer cell line (SW1116) was used for RT-PCR to clone the CEA fragments. The truncated or full-length CEA PCR product was cloned into a TA vector pCR II-TOPO to generate the plasmids pCR II-CEA and pCR II-CEAFL. Then, the truncated or full-length CEA fragment was inserted into a mammalian cell expression vector pCI-neo to construct plasmid pCI-CEA or pCI-CEAFL. To test the CEA protein expression, the RMA cell line was transfected with pCI-CEA or pCI-CEAFL to generate RMA-CEA or RMA-CEAFL cells. As shown in Fig. 1A, an 180-kDa CEA protein was detected in RMA-CEAFL cells but not in RMA-CEA cells. By immunohistochemistry staining (data not shown), the cell surface CEA expression was detected in RMA-CEAFL cells but not in RMA-CEA cells. Because the CEA polypeptide without NH2-terminal signal peptide should not be glycosylated without entering ER, we expected that the CEA protein in RMA-CEA cells would be ~80 kDa in molecular weight as reported previously (47). To confirm the truncated CEA polypeptide expression, pCR II-CEA was used for the in vitro transcription and translation assay with the rabbit reticulocyte lysate system. An ~80-kDa protein was detected after the in vitro transcription and translation using pCR II-CEA (Fig. 1B). Furthermore, the truncated CEA expression was detected in RMA-CEA cells by RT-PCR (Fig. 1C) and Western blotting analysis (Fig. 1D). The molecular weight of the CEA protein expressed in RMA-CEA cells was ~80 kDa.



View larger version (39K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Construction of expression plasmid pCI-CEA encoding human CEA without NH2-terminal signal peptide and plasmid pCI-CEAFL encoding the full-length CEA polypeptide with NH2-terminal signal peptide. A, soluble cell lysates of RMA, RMA-CEA, and RMA-CEAFL cells in the lysis buffer [1% Triton X-100, 20 mmol/L Tris-HCl (pH 7.6), 5 mmol/L EDTA] were separated by 8% SDS-PAGE and 1:1,000 diluted mouse anti-CEA antibody was used for the Western blotting assay. An ~180-kDa CEA protein was detected in RMA-CEAFL cells but not in RMA-CEA cells. B, the CEA fragment without a signal sequence was cloned into TA vector pCR II-TOPO to generate pCR II-CEA in which CEA is downstream of SP6 promoter. We use the plasmid pCR II-CEA to determine the CEA protein expression in vitro. The plasmid with the CEA fragment in the reverse orientation was used as the negative control. In TNT lysate reaction in the presence of rabbit reticulocyte lysate, SP6 RNA polymerase, [35S]methionine was used to label the newly synthesized protein from the DNA templates. 35S-labeled protein was detected by exposure to the X-ray film after separation by 8% SDS-PAGE. An ~80-kDa CEA protein was detected. C, RNA was extracted from RMA-CEA cells and RT-PCR was done to determine the mRNA expression of the truncated CEA. RMA cells transfected with empty vector (RMA-neo) were used as the negative control. The plasmid pCI-CEA was used as the positive control for PCR. ß-actin RT-PCR was done as the control. D, soluble cell lysates of RMA-neo and RMA-CEA were separated by 8% SDS-PAGE and 1:500 diluted mouse anti-CEA antibody was used for the Western blotting assay. An ~80 kDa CEA protein was detected in RMA-CEA cells. E, both PV-CEA and PV-CEAFL induced systemic CEA-specific CTL response in CEA-Tg mice by s.c. immunizations. Splenocytes isolated from CEA-Tg mice immunized with control VLPs (squares), PV-CEA (diamonds), or PV-CEAFL (triangles) were in vitro stimulated for 5 days with peptide 1 and used as effector cells for the 51Cr release assay at the different E:T ratios. After peptide 1 stimulation, effort cells were used to lyse target cells pulsed with peptide 1 (filled symbols) or no peptide (open symbols). Splenocytes isolated from individual mice were used for the experiments. Representative of six mice per group in two sets of experiments. P1-specific killing in both PV-CEA and PV-CEAFL groups was significantly higher than that in the control VLPs group (P < 0.05). The difference between PV-CEA and PV-CEAFL was not statistically significant.

 
Generation of papillomavirus pseudoviruses PV-CEA and PV-CEAFL and comparison of immunogenicities of PV-CEA and PV-CEAFL. BPV-1 VLPs were produced in Spodoptera frugiperda (Sf9) insect cells using a recombinant baculovirus encoding BPV-1 L1. BPV-1 VLPs were isolated and purified as we described previously (39). After dialysis, VLPs were disrupted in the buffer containing EGTA and DTT. The complete disruption of VLPs was confirmed by electronic microscopy as reported previously (39, 40). Plasmid pCI-CEA or pCI-CEAFL was added and the mixture was diluted by the reassembly buffer containing 25 mmol/L CaCl2 and 20% DMSO to form VLPs. Thus, L1 proteins were reassembled into VLPs and the plasmid DNA pCI-CEA or pCI-CEAFL was packaged inside of VLPs. The reassembled VLPs were confirmed by electronic microscopy as reported previously (39, 40). To confirm that the plasmid DNA was packaged inside of VLPs, the PV-CEA or PV-CEAFL pseudovirus preparation was treated with Benzonase to digest the DNA outside of VLPs. The plasmid DNA packaged inside of VLPs would not be digested by Benzonase. The sample then was heated to inactivate Benzonase and treated with proteinase K and SDS to digest the VLPs. The remaining plasmid DNA was extracted by phenol/chloroform and detected by running agarose gel and staining with ethidium bromide (39, 40). Because the PV-CEA and PV-CEAFL pseudoviruses are replication defective without the papillomavirus genome, we cannot determine the pseudovirus titers by traditional assays. Considering one VLP can package only one plasmid (40), we conclude that the copy number of the plasmid DNA inside of VLPs is equal to the number of pseudovirions. Therefore, we estimated the titers of PV-CEA and PV-CEAFL pseudoviruses as described in Materials and Methods.

When CEA was delivered in the context of viral forms, we expected peripheral immunologic tolerance to CEA in CEA-Tg mice would be broken as seen by other viral and bacterial vector-based CEA vaccines. To compare the immunogenicities of PV-CEA and PV-CEAFL, CEA-Tg mice were s.c. immunized twice at a 2-week interval with 20 µg BPV VLPs or ~0.8 x 1011 PV-CEA or PV-CEAFL pseudovirions generated from 20 µg BPV VLPs. Ten days after the second immunization, splenocytes were isolated to test systemic CEA-specific CTL responses. CEA526-533 is a known CEA-specific murine CTL epitope capable of inducing a CD8+ CTL response restricted by murine Db MHC class I molecules (9, 10, 48). We used this known epitope (peptide 1) to test CEA-specific, Db-restricted CTL response. As shown in Fig. 1E, both PV-CEA and PV-CEAFL induced systemic CEA-specific CTL response in CEA-Tg mice by s.c. immunizations. It suggests that PV-CEA and PV-CEAFL pseudoviruses can break the self-antigen tolerance to CEA. However, there was no significant difference in eliciting CEA-specific CTL response between PV-CEA and PV-CEAFL. We chose PV-CEA for the subsequent oral immunization experiments.

Carcinoembryonic antigen–specific CTL and antibody responses in carcinoembryonic antigen transgenic mice after oral immunization with PV-CEA pseudoviruses and antitumor immunity after tumor challenge. Previously, we showed that papillomavirus pseudoviruses encoding a target antigen pseudoinfected mucosal and systemic lymphoid tissues and induced mucosal and systemic CTL responses specific for the target antigen after oral immunization (39). Therefore, we hypothesized that PV-CEA pseudoviruses encoding human CEA could be used as an oral vaccine to induce mucosal and systemic CTL responses against CEA. To determine the immunogenicity of PV-CEA by oral immunization in CEA-Tg mice, mice were immunized twice at a 2-week interval by oral gavage with 20 µg BPV VLPs or ~0.8 x 1011 PV-CEA pseudovirions generated from 20 µg BPV VLPs. Ten days after the second immunization, mice were sacrificed and used to test CEA-specific CTL responses. If PV-CEA pseudoviruses induce mucosal and systemic CEA-specific CTL responses, we expect that CEA-specific CTLs induced in the Peyer's patches and spleen can lyse the H-2b target cells pulsed with H-2b-restricted, CEA-specific epitope peptides.

In addition to CEA526-533 (peptide 1), we searched for more Db-restricted CEA-specific CTL epitopes in this study. The amino acid sequence of human CEA (Genbank accession no. M17303) was scanned to predict Db-restricted CTL epitopes (nonamers) by using Peptide Binding Predictions (http://bimas.dcrt.nih.gov) and Peptide Predictions (www.syfpeithi.de). We combined the search results by two different methods and tested the following peptides as the CEA-specific, Db-restricted CTL epitope candidates: CEA355-363 (peptide 2), CEA100-108 (peptide 3), CEA347-355 (peptide 4), and CEA571-579 (peptide 5).

To test mucosal and systemic CEA-specific CTL responses in CEA-Tg mice, the lymphocytes isolated from Peyer's patches and spleen, respectively, were used for the in vitro 51Cr release assay. Peyer's patch lymphocytes were pooled from the mice (four mice per group) and were directly used as effector cells for the 51Cr release assay. As shown in Fig. 2, Peyer's patch lymphocytes isolated from mice orally immunized with PV-CEA pseudoviruses lysed RMA target cells pulsed with peptide 1 (CEA526-533) and peptide 5 (CEA571-579). In contrast, Peyer's patch lymphocytes from the control mice orally immunized with VLPs did not. RMA target cells pulsed with peptides 2 to 4 were not lysed by Peyer's patch lymphocytes from mice orally immunized with PV-CEA pseudoviruses. Our data showed that oral immunization of PV-CEA induced mucosal CEA526-533-specific and CEA571-579-specific CTL responses in CEA-Tg mice. It indicates that CEA571-579 is a H-2b-restricted, CEA-specific CTL epitope. T-cell-enriched splenocytes isolated from immunized mice were in vitro stimulated for 5 days with peptides 1 to 5, respectively. Then, stimulated splenocytes were used as effector cells for the 51Cr release assay to lyse the corresponding target cells pulsed with peptides 1 to 5, respectively. We found that splenocytes from mice orally immunized with PV-CEA lysed RMA target cells pulsed with peptide 1 (CEA526-533) or peptide 5 (CEA571-579) after in vitro stimulation with peptide 1 or 5, respectively (Fig. 3A). However, splenocytes stimulated with other peptides did not (data not shown). It suggests that oral immunization with PV-CEA pseudoviruses also induces systemic CEA-specific CTL response in CEA-Tg mice. Therefore, PV-CEA pseudoviruses can induce both mucosal and systemic CEA-specific CTL responses in CEA-Tg mice by oral immunization. Our data also suggest that peptide 5 (CEA571-579) is a novel H-2b restricted, CEA-specific CTL epitope.



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Mucosal CEA-specific cytolytic activity in CEA-Tg mice after oral immunization with PV-CEA pseudoviruses. Peyer's patch lymphocytes freshly isolated from CEA-Tg mice immunized with PV-CEA ({blacksquare}) or VLPs ({blacklozenge}) were pooled and directly used as the effector cells at different E:T ratios for the 6-hour in vitro 51Cr release assay. RMA cells pulsed with peptides 1 to 5, respectively, were used as target cells. All experiments were done thrice. Representative results.

 


View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Systemic CEA-specific CTL and antibody responses in CEA-Tg mice after oral immunization with PV-CEA pseudoviruses. A, splenocytes isolated from CEA-Tg mice immunized with PV-CEA (squares) or VLPs (diamonds) were in vitro stimulated for 5 days with peptide 1 (left) or peptide 5 (right) and used as effector cells for the 51Cr release assay at the different E:T ratios. Left, after peptide 1 stimulation, effort cells were used to lyse target cells pulsed with peptide 1 (filled symbols) or LCMV peptide (open symbols); right, after peptide 5 stimulation, effector cells were used to lyse target cells pulsed with peptide 5 (filled symbols) or LCMV peptide (open symbols). Splenocytes isolated from individual mice were used for the experiments. Representative of >12 mice per group in three sets of experiments. B, samples from CEA-Tg mice orally immunized with PV-CEA, PV-CEAFL, or BPV VLPs were used for ELISA to detect anti-CEA IgG/IgM antibodies in sera (left) and anti-CEA IgA antibodies in intestinal washings (right). Representative of four mice in each group.

 
We also used the IFN-{gamma} ELISPOT assay to determine CEA-specific IFN-{gamma}-secreting cells in Peyer's patches and spleen in CEA-Tg mice after oral immunization with VLPs or PV-CEA pseudoviruses. Using CEA-specific CTL epitope peptides to stimulate lymphocytes, we expected responder cells secreting INF-{gamma} should be CEA epitope-specific CTLs. With or without exogenous Db-restricted, CEA-specific epitope peptide stimulation, there were significantly more IFN-{gamma}-secreting cells in the Peyer's patch lymphocytes from CEA-Tg mice orally immunized with PV-CEA compared with the control mice immunized with VLPs (data not shown). For the splenocytes, we also found that there were more IFN-{gamma}-secreting cells in mice immunized with PV-CEA with or without exogenous CEA-specific CTL epitope peptides (data not shown). We reasoned that endogenous CEA from CEA-Tg mice were processed and presented by CEA+ cells or APCs, which stimulated CEA-specific CD4+ and CD8+ T cells to secret IFN-{gamma} during in vitro culture, even without adding exogenous Db-restricted, CEA-specific epitope peptides. Actually, CEA-Tg mice even have a high level of CEA in the serum besides the CEA expression on the normal intestinal epithelial cells (9).

We did not expect that oral immunization of PV-CEA could induce a significant level of anti-CEA antibody response because the truncated CEA polypeptide without NH2-terminal signal peptide was not expressed on the cell surface and the protein was not stable. As shown in Fig. 3B, no anti-CEA IgG/IgM levels in sera (left) or IgA levels in intestinal washings (right) were detected in CEA-Tg mice orally immunized with BPV VLPs or PV-CEA. However, as we expected, there were anti-CEA antibodies in both sera and intestinal washings in CEA-Tg mice orally immunized with PV-CEAFL, because the full-length CEA was expressed on the cell surface.

Oral immunization of PV-CEA induced CEA-specific CTL response but no antibody responses. It was of interest to determine whether oral immunization with PV-CEA provides antitumor effect against a challenge with CEA+ tumors. We compared the growth of CEA+ tumor cells in CEA-Tg mice orally immunized with PV-CEA or control BPV VLPs. One week after the second immunization, 1 x 106 RMA-CEAFL cells were s.c. injected into mice. As shown in Fig. 4, the tumor growth rates were significantly delayed in CEA-Tg mice orally immunized with PV-CEA when compared with mice treated with the control BPV VLPs (P < 0.05).



View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Antitumor efficacy of oral PV-CEA vaccine. CEA-Tg mice were orally immunized with PV-CEA or BPV VLPs. One week after the second immunization, 1 x 106 RMA-CEAFL cells were s.c. injected into mice. Average tumor growth of all six mice each group. Points, mean for six mice; bars, SD. The experiments were done twice. Representative results. The difference between two groups was significant (P < 0.05). {blacklozenge}, VLPs; {blacksquare}, PV-CEA.

 
The truncated carcinoembryonic antigen delivered by PV-CEA pseudoviruses was immunogenic in the context of human MHC HLA-A2. To develop a human vaccine, our ultimate goal is to induce human CEA-specific T-cell responses. Several human CEA-specific, A2-restricted epitopes have been identified. Therefore, we wanted to determine whether CEA-specific antigenic epitopes can be presented on human MHC class I molecules and induce CEA-specific human epitope-specific CTL responses in an animal model. A2-Tg mice express both murine H-2b molecules and transgenic human HLA-A2 molecules, which provides a critical preclinical screening model for a human vaccine. Additionally, PV-CEA pseudoviruses encode a truncated CEA without the signal peptide, which alters the CEA protein synthesis, modification, degradation, and antigen processing pathways. Therefore, it is important to determine whether the truncated CEA can be processed to present human A2-restricted epitopes on A2 molecules. CAP-1 is a HLA-A2-restricted CEA-specific CTL epitope (49). Thus, we used CAP-1 to determine mucosal and systemic A2-restricted CTL responses against CEA in A2-Tg mice after oral immunization with PV-CEA pseudoviruses.

To determine whether CAP-1-specific CTLs were induced in A2-Tg mice orally immunized with PV-CEA pseudoviruses, we did the in vitro 51Cr release assay for the cytolytic activity of CTLs using lymphocytes isolated from Peyer's patches and spleen as effector cells (Fig. 5A). We found that CAP-1-specific cytolytic activity was only marginally above the background for the Peyer's patch lymphocytes from A2-Tg mice orally immunized with PV-CEA pseudoviruses compared with the controls. However, CAP-1-specific cytolytic activity was strong for the splenocytes from A2-Tg mice orally immunized with PV-CEA pseudoviruses after in vitro stimulation for 5 days with CAP-1. In contrast, there were no CAP-1-specific cytolytic activities for the lymphocytes of Peyer's patches and spleen from the mice orally immunized with VLPs.



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Mucosal and systemic CEA-specific CTL response in HLA-A2-Tg mice after oral immunization with PV-CEA pseudoviruses. A, mucosal and systemic CEA-specific cytolytic activity: Peyer's patch lymphocytes and splenocytes were isolated from CEA-Tg mice immunized with PV-CEA (squares) or VLPs (diamonds). Left, freshly isolated Peyer's patch lymphocytes were pooled in each group and directly used as effector cells to lyse EL4-A2Kb target cells pulsed with CAP-1 (filled symbols) or the control HIV peptide (open symbols). Representative of two different experiments. Right, splenocytes were in vitro stimulated with CAP-1 for 5 days and then used as the effector cells. EL4-A2Kb cells pulsed with CAP-1 (filled symbols) or the HIV peptide (open symbols) were used as the target cells. Splenocytes isolated from individual mice were used for the experiments. Representative of >12 mice per group in three sets of experiments. B, mucosal and systemic HLA-A2-restricted, CAP-1-specific, IFN-{gamma}-secreting cells were detected by the IFN-{gamma} ELISPOT assay. Peyer's patch lymphocytes (left) and splenocytes (right) were isolated from A2-Tg mice orally immunized with PV-CEA (filled column) or VLPs (open column) and used as the responder cells. The splenocytes isolated from naive mice were used as the feeder cells in the presence of CAP-1 or the control HIV peptide. Left, numbers of IFN-{gamma}-secreting cells in 1 x 105 Peyer's patch lymphocytes pooled from four mice per group. The difference between VLPs and PV-CEA is significant in response to CAP-1 stimulation (P < 0.05). Right, numbers of IFN-{gamma}-secreting cells in 1 x 106 splenocytes from individual mice. The difference between VLPs and PV-CEA is significant in response to CAP-1 stimulation (P < 0.05). All experiments were done thrice. Representative results.

 
Furthermore, Peyer's patch lymphocytes and splenocytes isolated from A2-Tg mice immunized with VLPs or PV-CEA were used as responder cells for the IFN-{gamma} ELISPOT assays. CAP-1 was used for in vitro stimulation for 40 hours and A2-restricted HIV-1 gp160120-128 peptide was used as the control. The results (Fig. 5B) showed that there were more A2-restricted, CAP-1-specific, INF-{gamma}-secreting cells for lymphocytes obtained from both Peyer's patches and spleen in mice orally immunized with PV-CEA than those from mice orally immunized with VLPs. After in vitro stimulation with the control HIV peptide, there were only the background levels of IFN-{gamma}-secreting cells for both Peyer's patches and spleen.

The combination of the ELISPOT and cytotoxicity assay data showed that oral immunization with PV-CEA pseudoviruses induced mucosal and systemic A2-restricted CAP-1-specific CTL responses in A2-Tg mice. However, the cytolytic activity of mucosal Peyer's patch lymphocytes was only at a marginal level in the 51Cr release assay without in vitro stimulation to amplify CAP-1-specific CTLs.

The immunogenicity of PV-CEA pseudoviruses in aged carcinoembryonic antigen/A2 double transgenic mice. Many patients with CEA+ colorectal tumors are elderly individuals. Therefore, it is important to test whether PV-CEA pseudoviruses are immunogenic in aged CEA/A2 double transgenic mice, which provides a more clinically relevant model. CEA/A2 double transgenic mice express human CEA and carry both murine H-2b and human HLA-A2 molecules (data not shown). There were neither H-2b-restricted nor A2-restricted, CEA-specific CTL responses to endogenous CEA in 6- to 8-week-old CEA/A2 double transgenic mice (data not shown), which suggests a peripheral CD8+ T-cell tolerance to CEA (data not shown). Previously, we showed that aged mice did not respond well to immunization with papillomavirus pseudoviruses, which was most likely due to age-related reduction of IL-2 production by T cells (41). Delivery of IL-2 by papillomavirus pseudoviruses encoding IL-2 restored the immune responses to papillomavirus pseudovirus vaccinations (41).

We defined mice >1 year old as aged mice. Aged mice were orally immunized twice with PV-CEA pseudoviruses, PV-CEA pseudoviruses plus PV-IL-2 pseudoviruses, or VLPs alone. Ten days after the second immunization, mice were sacrificed and splenocytes were isolated to determine whether PV-CEA pseudoviruses were immunogenic in aged mice and whether coadministration of PV-IL-2 would enhance CEA-specific CTL response induced by PV-CEA pseudoviruses (Fig. 6). We found that there was only a marginal level of CAP-1-specific CTL response for the splenocytes from aged CEA/A2 double transgenic mice orally immunized with PV-CEA pseudoviruses, and coadministration of PV-IL-2 pseudoviruses with PV-CEA pseudoviruses enhanced CAP-1-specific CTL response for the splenocytes from aged CEA/A2 double transgenic mice.



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. Coadministration of PV-IL-2 enhances the CEA-specific CTL response in aged CEA/A2 double transgenic mice after oral immunization with PV-CEA pseudoviruses. Twelve-month-old CEA/A2 double transgenic mice were orally immunized with VLPs (diamonds), PV-CEA (squares), or PV-CEA plus PV-IL-2 (triangles). The splenocytes isolated from immunized mice were in vitro stimulated with CAP-1 peptide for 5 days and used as the effector cells for the in vitro 51Cr release assay. Top, EL4-A2Kb cells pulsed with the control HIV peptide were used as the target cells; bottom, EL4-A2Kb cells pulsed with CAP-1 were used as the target cells. Representative of two different experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The rationale for a therapeutic tumor vaccine is to induce and maintain tumor-specific CTLs capable of eliminating tumor cells. CEA is a tumor-associated antigen expressed at a high level in the majority of colorectal tumor cells but at a very low level in the normal intestinal epithelia. Therefore, CEA is used as a target antigen for the development of a therapeutic vaccine against CEA+ colorectal tumors. CEA+ colorectal tumors are mainly located on the gastrointestinal mucosal surface. Ideally, CEA-specific CTLs induced by a CEA vaccine should be able to localize in the local mucosal area and efficiently lyse neighboring CEA+ tumor cells. In addition, the vaccine has to break the tolerance to CEA as a self-antigen. Considering systemic immunization in general does not induce mucosal CTLs (50), we delivered plasmid DNA encoding CEA in the context of mucosatropic papillomavirus VLPs (PV-CEA pseudovirus) to mucosal lymphoid tissues by oral immunization. We have shown that oral immunization with PV-CEA induced both mucosal and systemic CTLs in CEA-Tg mice, indicating that PV-CEA pseudoviruses can break the peripheral self-tolerance to CEA. We believe that APC in Peyer's patches and other lymphoid tissues can take up PV-CEA pseudoviruses and the encoded CEA is expressed by these APCs, which induce both mucosal and systemic CEA-specific CTLs. We also believe that the VLPs render APCs more immunogenic so that the tolerance to CEA is overcome in CEA-Tg mice. To our knowledge, this is the first report directly showing the CEA-specific CTL response in the mucosa after oral immunization with an oral CEA vaccine.

In this study, we identified a novel H-2b-restricted, CEA-specific CTL epitope CEA571-579 after screening four predicted Db-restricted CTL epitope candidates for CEA. This new epitope is similar to the known epitope CEA526-533 in that the extent of the CTL responses specific for them is similar. Although PV-CEA induced CTLs that lysed RMA target cells pulsed with these two epitope peptides, neither RMA-CEA nor RMA-CEAFL cells expressing CEA were lysed when used as target cells (data not shown). The data were similar to the observation that a H-2 Db-restricted CD8+ CTL line specific for CEA526-533 peptide efficiently lysed peptide-pulsed targets but not CEA-expressing tumor cells (48). These two epitope-specific CTLs might be low-avidity cytotoxic T cells, which are able to lyse target cells directly pulsed with peptides but not tumor cells expressing CEA (48). In an in vivo tumor challenge model, we showed that oral immunization with PV-CEA could delay the tumor growth rate after CEA+ tumor challenge. It suggests that CEA-specific CD8+ CTLs induced by PV-CEA can kill CEA+ tumors in vivo and provide antitumor effect against CEA+ tumors. However, no CEA-Tg mice orally immunized with PV-CEA completely reject tumors. It might be due to a very high dose of tumor cells used for the challenge. The multiple immunizations and/or the coadministration of effective vaccine adjuvants might be required to enhance immune responses for successful tumor prevention.

The IFN-{gamma} ELISPOT assay was used for the functional detection of T-cell activation. CEA-specific epitope peptides were added to stimulate T cells. However, we found the endogenous CEA expressed in CEA-Tg mice interfered with the results of addition of exogenous CEA-specific CTL peptides in the ELISPOT assay. In that case, IFN-{gamma}-secreting cells should include both CEA-specific CD4+ and CD8+ T cells. In Zhou et al.'s ELISPOT assays (51), there were a very high number of IFN-{gamma}-secreting cells in CEA-Tg mice vaccinated with CEA vaccines even without CEA peptide stimulation when compared with the control vaccination groups. It was similar to our findings in CEA-Tg mice. Therefore, the IFN-{gamma} ELISPOT assay cannot be used to indicate the CD8+ CTLs specific for one particular epitope very well in the presence of endogenous CEA in CEA-Tg mice. In the subsequent experiments using CEA/A2 double transgenic mice, we did not use the IFN-{gamma} ELISPOT assay to monitor CEA-specific CTLs.

CAP-1 is an A2-restricted CEA-specific CTL epitope. Oral immunization with PV-CEA in A2-Tg mice induced CAP-1-specific cytolytic activity among splenocytes after in vitro stimulation with CAP-1 peptide for 5 days. However, in mice orally immunized with PV-CEA pseudoviruses, no significant CAP-1-specific cytolytic activity was detected among lymphocytes freshly isolated from Peyer's patches without in vitro CAP-1 stimulation. Mice and humans harbor different T-cell receptor repertoires. CAP-1 might not be an immunodominant CTL epitope of CEA in A2-Tg mice. Therefore, not enough CAP-1-specific CTLs were induced by immunization. Without in vitro amplification of CAP-1-specific CTLs by CAP-1 stimulation, no significant cytolytic activity can be detected. We further used the IFN-{gamma} ELISPOT assay to determine the number of CAP-1-specific, IFN-{gamma}-secreting cells in Peyer's patch lymphocytes and splenocytes after in vitro stimulation with CAP-1 for 40 hours. There were more CAP-1-specific, IFN-{gamma}-secreting cells in Peyer's patches and spleen from mice orally immunized with PV-CEA pseudoviruses compared with the control mice immunized with VLPs. Our 51Cr release assay data combined with the ELISPOT data suggest that oral immunization with PV-CEA pseudoviruses can induce mucosal and systemic CAP-1-specific CTL response in A2-Tg mice.

Finally, we used a more clinically relevant animal model, aged CEA/A2 double transgenic mice, to test our human CEA vaccine. PV-CEA pseudoviruses induced only a marginal level of CAP-1-specific cytolytic activity in aged CEA/A2 double transgenic mice by oral immunization. Coadministration of PV-IL-2 pseudoviruses enhanced CAP-1-specific CTL response to PV-CEA pseudovirus vaccine. IL-2 production is deficient in CD4+ T cells in aged mice (52, 53). It was reported that combination with IL-2 improved the immunotherapy of a recombinant CEA vaccinia vaccine even in young mice (11, 54). Our data suggest that oral immunization with PV-CEA pseudovirus vaccine can induce HLA-A2-restricted, CEA-specific CTL response in CEA/A2 double transgenic mice. It implies that PV-CEA pseudovirus vaccine is a promising oral CEA tumor vaccine for humans. Coadministration of PV-IL-2 pseudoviruses might enhance the effect of PV-CEA pseudovirus vaccine in the elderly who do not respond well to vaccinations.


   Acknowledgments
 
Grant support: American Cancer Society grant RSG-02-247-01-MBC (L. Qiao).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank the members of the Qiao laboratory for helpful suggestions, Drs. John W. Greiner and Jeffrey Schlom for kindly providing CEA-Tg mice, and Dr. W.M. Kast for the gift of the EL4-A2Kb cells.

Received 10/13/04. Revised 5/11/05. Accepted 5/18/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Muraro R, Wunderlich D, Thor A, et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985;45:5769–80.[Abstract/Free Full Text]
  2. Steward AM, Nixon D, Zamcheck N, Aisenberg A. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 1974;33:1246–52.[CrossRef][Medline]
  3. Vincent RG, Chu TM, Lane WW, Gutierrez AC, Stegemann PJ, Madajewicz S. Carcinoembryonic antigen as a monitor of successful surgical resection in 130 patients with carcinoma of the lung. J Thorac Cardiovasc Surg 1978;75:734–9.[Medline]
  4. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002;20:2197–207.[Abstract/Free Full Text]
  5. Hasegawa T, Isobe K, Tsuchiya Y, et al. Establishment and characterisation of human carcinoembryonic antigen transgenic mice. Br J Cancer 1991;64:710–4.[Medline]
  6. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169–76.[Abstract/Free Full Text]
  7. Thompson JA, Eades-Perner AM, Ditter M, Muller WJ, Zimmermann W. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Int J Cancer 1997;72:197–202.[CrossRef][Medline]
  8. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998;58:1469–77.[Abstract/Free Full Text]
  9. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676–83.[Abstract/Free Full Text]
  10. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206–14.[Abstract/Free Full Text]
  11. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770–7.[Abstract/Free Full Text]
  12. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002;62:6944–51.[Abstract/Free Full Text]
  13. Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L, Schlom J. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003;63:7942–9.[Abstract/Free Full Text]
  14. Mizobata S, Tompkins K, Simpson JF, Shyr Y, Primus FJ. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 2000;49:285–95.[CrossRef][Medline]
  15. Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res 2003;63:2844–54.[Abstract/Free Full Text]
  16. Saha A, Chatterjee SK, Foon KA, et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004;64:4995–5003.[Abstract/Free Full Text]
  17. Luo Y, O'Hagan D, Zhou H, et al. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003;21:1938–47.[CrossRef][Medline]
  18. Xiang R, Silletti S, Lode HN, et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res 2001;7:856–64s.
  19. Niethammer AG, Primus FJ, Xiang R, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 2001;20:421–9.[CrossRef][Medline]
  20. Xiang R, Primus FJ, Ruehlmann JM, et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001;167:4560–5.[Abstract/Free Full Text]
  21. Ras E, van der Burg SH, Zegveld ST, et al. Identification of potential HLA-A*0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 1997;53:81–9.[CrossRef][Medline]
  22. Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998;59:1–14.[Medline]
  23. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999;59:431–5.[Abstract/Free Full Text]
  24. Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998;47:90–6.[CrossRef][Medline]
  25. Kim CH, Todoroki T, Matsumura M, Ohno T. Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen. J Cancer Res Clin Oncol 2000;126:383–90.[CrossRef][Medline]
  26. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 1999;80:92–7.[CrossRef][Medline]
  27. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3:2439–49.[Abstract/Free Full Text]
  28. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332–7.[Abstract/Free Full Text]
  29. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24–33.[Abstract/Free Full Text]
  30. Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999;82:121–4.[CrossRef][Medline]
  31. Galloway DA. Is vaccination against human papillomavirus a possibility? Lancet 1998;351 Suppl 3:22–4.[Medline]
  32. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992;89:12180–4.[Abstract/Free Full Text]
  33. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997;65:3328–36.[Abstract]
  34. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993;67:1936–44.[Abstract/Free Full Text]
  35. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 1996;7:373–82.[CrossRef][Medline]
  36. Volpers C, Schirmacher P, Streeck RE, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994;200:504–12.[CrossRef][Medline]
  37. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 1998;72:10298–300.[Abstract/Free Full Text]
  38. Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998;26:1317–23.[Abstract/Free Full Text]
  39. Shi W, Liu J, Huang Y, Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 2001;75:10139–48.[Abstract/Free Full Text]
  40. Zhang H, Fayad R, Wang X, Quinn D, Qiao L. Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J Virol 2004;78:10249–57.[Abstract/Free Full Text]
  41. Fayad R, Zhang H, Quinn D, Huang Y, Qiao L. Oral administration with papillomavirus pseudovirus encoding IL-2 fully restores mucosal and systemic immune responses to vaccinations in aged mice. J Immunol 2004;173:2692–8.[Abstract/Free Full Text]
  42. Eiben GL, Velders MP, Schreiber H, et al. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002;62:5792–9.[Abstract/Free Full Text]
  43. Townsend A, Bastin J, Gould K, et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988;168:1211–24.[Abstract/Free Full Text]
  44. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997;185:909–20.[Abstract/Free Full Text]
  45. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 1999;73:7877–81.[Abstract/Free Full Text]
  46. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344–66.[Medline]
  47. Ansardi DC, Moldoveanu Z, Porter DC, et al. Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res 1994;54:6359–64.[Abstract/Free Full Text]
  48. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-{gamma}-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 2002;62:5058–64.[Abstract/Free Full Text]
  49. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982–90.[Abstract/Free Full Text]
  50. Fujihashi K, Dohi T, Rennert PD, et al. Peyer's patches are required for oral tolerance to proteins. Proc Natl Acad Sci U S A 2001;98:3310–5.[Abstract/Free Full Text]
  51. Zhou H, Luo Y, Mizutani M, et al. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 2004;113:1792–8.[CrossRef][Medline]
  52. Haynes L, Eaton SM, Swain SL. The defects in effector generation associated with aging can be reversed by addition of IL-2 but not other related {gamma}(c)-receptor binding cytokines. Vaccine 2000;18:1649–53.[CrossRef][Medline]
  53. Thoman ML, Weigle WO. Reconstitution of in vivo cell-mediated lympholysis responses in aged mice with interleukin 2. J Immunol 1985;134:949–52.[Abstract]
  54. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361–7.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Kim-Schulze, H. S. Kim, A. Wainstein, D. W. Kim, W. C. Yang, D. Moroziewicz, P. Y. Mong, M. Bereta, B. Taback, Q. Wang, et al.
Intrarectal Vaccination with Recombinant Vaccinia Virus Expressing Carcinoembronic Antigen Induces Mucosal and Systemic Immunity and Prevents Progression of Colorectal Cancer
J. Immunol., December 1, 2008; 181(11): 8112 - 8119.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Saha, S. K. Chatterjee, K. A. Foon, E. Celis, and M. Bhattacharya-Chatterjee
Therapy of Established Tumors in a Novel Murine Model Transgenic for Human Carcinoembryonic Antigen and HLA-A2 with a Combination of Anti-idiotype Vaccine and CTL Peptides of Carcinoembryonic Antigen
Cancer Res., March 15, 2007; 67(6): 2881 - 2892.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, A. T. Remaley, M. L. Sampson, J. Zhang, D. D. Cox, J. Pingpank, R. Alexander, M. Willingham, I. Pastan, and M. Onda
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 447 - 453.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, Y.
Right arrow Articles by Qiao, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, Y.
Right arrow Articles by Qiao, L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online